However, the results of the ESTIMATE algorithm showed that patients with high-risk had a higher immune score and stromal score and a higher expression level of PD-L2 and CTLA4, which indicated that patients with a high-risk score had a more complex tumor immune microenvironment and more immune cell infiltration, although the immune cell infiltration in high-risk tumors did not show an anti-tumor effect. The gene discussed is PDCD1LG2; the disease is neoplasm.